首页> 外文OA文献 >Comparison between the first-line and second-line immunotherapy drugs in the progression-free survival and overall survival in advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials

【2h】

Comparison between the first-line and second-line immunotherapy drugs in the progression-free survival and overall survival in advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials

机译：第一线和二线免疫疗法在进展的无进展生存和全面存活中的比较：随机对照试验的系统评价和荟萃分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Shengyu Wu; Lei Wang; Wei Li; Bin Chen; Yu Liu; Hao Wang; Sha Zhao; Lingyun Ye; Hui Sun; Yayi He;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating the First-Line Chemotherapy for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma [J] . Nakashima Kentaro, Horita Nobuyuki, Nagai Kenjiro, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2016,第9期

机译：无进展的存活，反应率和疾病控制率作为III期随机对照试验的总体存活率的预测因子，评估先进，局部晚期和复发非小细胞肺癌的一线化疗
2. The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials [J] . Hasegawa Yoshikazu, Ando Masahiko, Maemondo Makoto, The oncologist . 2015,第3期

机译：吸烟状态在非活化小细胞肺癌患者无进展生存中的作用，该患者具有接受一线EGFR酪氨酸激酶抑制剂与铂类双重治疗的活化表皮生长因子受体（EGFR）突变：前瞻性随机试验的荟萃分析。
3. The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials [J] . Yoshikazu Hasegawa, Masahiko Ando, Makoto Maemondo, The oncologist . 2015,第3期

机译：吸烟状态对非小细胞肺癌患者无进展生存的作用
4. Development and validation of a radiomics nomogram for progression-free survival prediction in stage IV EGFR-mutant non-small cell lung cancer [C] . Jiangdian Song, Yali Zang, Weimin Li, Conference on Computer-Aided Diagnosis . 2017

机译：放射组学诺模图的开发和验证，用于IV期EGFR突变非小细胞肺癌的无进展生存期预测
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials [O] . Yoshikazu Hasegawa, Masahiko Ando, Makoto Maemondo, 2015

机译：吸烟状态在非小细胞肺癌患者无进展生存中的作用该患者具有接受一线EGFR酪氨酸激酶抑制剂对铂类双重化疗的活化表皮生长因子受体（EGFR）突变：前瞻性随机试验的Meta分析。
7. Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials [O] . Aung Myint Tun, Kyaw Zin Thein, Wai Lin Thein, 2019

机译：检查点抑制剂加上化疗进行先进的非小细胞肺癌的一线治疗：随机对照试验进行系统审查和荟萃分析

Comparison between the first-line and second-line immunotherapy drugs in the progression-free survival and overall survival in advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials

著录项

引文网络

相似文献

相关主题

期刊订阅